 SOUTH SAN FRANCISCO, Calif., March 08, 2021 GLOBE NEWSWIRE -- Aligos Therapeutics, Inc. Nasdaq: ALGS, a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company delivered a presentation on its SARS-CoV-2 3CLpro inhibitor candidate, ALG-097111, at the 28th Conference on Retroviruses and Opportunistic Infections, being held virtually March 6 to March 10, 2021, during the meetings Science Spotlight sessions on Saturday, March 6. Aligos performed all research in collaboration with Belgian University KU Leuven, in particular its Centre for Drug Design and Discovery CD3, and the Rega Institute for Medical Research. 